Semaglutide is another GLP-1RA that has also gained interest in the treatment of steatohepatitis, as several studies in patients with T2DM and obesity reported beneficial changes in liver enzymes and inflammatory biomarkers such as high-sensitivity C-reactive protein [80,81]. The gene discussed is CRP; the disease is obesity disorder.